Bio-Techne is expected to report Q1 2027 revenue of $284.1 million and adjusted EPS of $0.41, while the current stock price of $74.20 remains roughly 14% below the $84.50 analyst average price target. Investors are primarily focused on the organic revenue growth rate, which is projected to reach 5.1% as the company moves past pandemic-era comparisons.

The report is expected to show a stabilization in the Protein Sciences segment, which has faced headwinds from inventory destocking in the biopharma sector over the last year. Management’s commentary on demand recovery in the China market and the continued integration of cell and gene therapy acquisitions will be critical for maintaining full-year fiscal guidance.